[Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases: a randomized, double-blind, multi-doses, active drug controlled, multi-center study].
Zhonghua Gan Zang Bing Za Zhi
; 17(11): 847-51, 2009 Nov.
Article
em Zh
| MEDLINE
| ID: mdl-19958646
ABSTRACT
OBJECTIVE:
To evaluate the efficacy and safety of Magnesium isoglycyrrhizinate in treatment of chronic liver diseases.METHODS:
It is a randomized, double-blind, multi-doses, active drug controlled, multi-center study. 480 proper patients were randomly divided into group A (180 patients), group B (180 patients) or group C (120 patients). Patients in group A received magnesium isoglycyrrhizinate 100 mg once daily. Patients in group B received magnesium isoglycyrrhizinate 150 mg once daily. Patients in group C received compound glycyrrhizin 120 mg once daily. The treatment course was 4 weeks. Patients were followed up 2 weeks after the treatment. Patients visited once every 2 weeks. Clinical symptoms, ALT, AST were evaluated in all the patients before treatment, at week 2, at week 4 and at 2 weeks later after treatment. The other liver function test was done before treatment and at week 4.RESULTS:
412 patients completed the study according to the protocol,152 in group A, 160 in group B and 100 in group C. ALT and AST level were significantly decreased in all groups at week 2 and week 4 (P < 0.05). The degree of ALT decrease is greater in group B than in group C at week 2 (P < 0.01). The degree of ALT decrease was not significant different among three groups at week 4 (P > 0.05). The rates of ALT improvement at week 4 in group A, B, C were 92.59%, 91.76%, 88.29%, respectively (P > 0.05). The rates of symptoms improvement at week 4 in group A, B, C were 90.41%, 89.86%, 86.46% and 72.22%, 73.53%, 68.47%, respectively (P > 0.05). No relapse were found in all three groups after treatment. The rate of adverse event in three groups was similar (P > 0.05).CONCLUSION:
Magnesium isoglycyrrhizinate is an effective and safe treatment for chronic liver diseases.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Saponinas
/
Triterpenos
/
Ácido Glicirrízico
/
Alanina Transaminase
/
Hepatopatias
/
Anti-Inflamatórios
Tipo de estudo:
Clinical_trials
/
Guideline
Limite:
Female
/
Humans
/
Male
Idioma:
Zh
Ano de publicação:
2009
Tipo de documento:
Article